title: Neurexin-1α contributes to insulin-containing secretory granule docking.
abstract: Neurexins are a family of transmembrane, synaptic adhesion molecules. In neurons, neurexins bind to both sub-plasma membrane and synaptic vesicle-associated constituents of the secretory machinery, play a key role in the organization and stabilization of the presynaptic active zone, and help mediate docking of synaptic vesicles. We have previously shown that neurexins, like many other protein constituents of the neurotransmitter exocytotic machinery, are expressed in pancreatic β cells. We hypothesized that the role of neurexins in β cells parallels their role in neurons, with β-cell neurexins helping to mediate insulin granule docking and secretion. Here we demonstrate that β cells express a more restricted pattern of neurexin transcripts than neurons, with a clear predominance of neurexin-1α expressed in isolated islets. Using INS-1E β cells, we found that neurexin-1α interacts with membrane-bound components of the secretory granule-docking machinery and with the granule-associated protein granuphilin. Decreased expression of neurexin-1α, like decreased expression of granuphilin, reduces granule docking at the β-cell membrane and improves insulin secretion. Perifusion of neurexin-1α KO mouse islets revealed a significant increase in second-phase insulin secretion with a trend toward increased first-phase secretion. Upon glucose stimulation, neurexin-1α protein levels decrease. This glucose-induced down-regulation may enhance glucose-stimulated insulin secretion. We conclude that neurexin-1α is a component of the β-cell secretory machinery and contributes to secretory granule docking, most likely through interactions with granuphilin. Neurexin-1α is the only transmembrane component of the docking machinery identified thus far. Our findings provide new insights into the mechanisms of insulin granule docking and exocytosis.
authors.affiliation: Pediatric Diabetes Research Center, Veterans Affairs San Diego Healthcare System, University of California San Diego, La Jolla, California 92093, USA.
authors.forename: Merrie
authors.initials: M
authors.lastname: Mosedale
authors.forename: Sonya
authors.initials: S
authors.lastname: Egodage
authors.forename: Rei C
authors.initials: RC
authors.lastname: Calma
authors.forename: Nai-Wen
authors.initials: NW
authors.lastname: Chi
authors.forename: Steven D
authors.initials: SD
authors.lastname: Chessler
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D005089:Exocytosis / Q000502:physiology*; D015870:Gene Expression / Q000502:physiology; D005947:Glucose / Q000494:pharmacology; D006023:Glycoproteins / Q000235:genetics / Q000378:metabolism*; D007328:Insulin / Q000235:genetics / Q000378:metabolism*; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009479:Neuropeptides / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D034741:RNA, Small Interfering / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D022142:Secretory Vesicles / Q000378:metabolism*
chemical_list: D006023:Glycoproteins; D007328:Insulin; D009479:Neuropeptides; D012333:RNA, Messenger; D034741:RNA, Small Interfering; C112162:neurexophilin; D005947:Glucose